{"schema_version":"1.0","type":"article","title":"類固醇減不下來，諾華多一條路","url":"https://drugnews.com.tw/articles/2026-11-22-cosentyx-pmr-steroid-taper.html","markdown_url":"https://drugnews.com.tw/articles/2026-11-22-cosentyx-pmr-steroid-taper.md","lang":"zh-Hant","date":"2026-11-22","publish_at":"2026-11-22T08:00:00+08:00","updated_at":"2026-11-22","category":"商業分析系列","topic":"臨床與 CMC","tags":["PMR","風濕性多肌痛症","類固醇","Cosentyx"],"summary":"Cosentyx美國多肌痛新適應症增加減類固醇的選擇；持續緩解、監測與在地可近性，才決定病人實際得到什麼。","key_points":["Cosentyx增加PMR減類固醇的選擇；差異化須比較持續緩解、減量流程及安全性，現有資料沒有與Kevzara直接比較。","REPLENISH比較指定減量流程下的組間差，沒有與Kevzara直接對打。","美國新適應症與台灣在地許可、給付是不同問題。"],"facts":[{"claim":"最早公開台北日期","value":"2026-11-17","unit":"date","as_of":"2026-11-17","source":"https://via.ritzau.dk/files/90446/15292906/612691/en"},{"claim":"台北最早公開時間","value":"2026-11-17T10:43:00+08:00","unit":"datetime","as_of":"2026-11-17","source":"https://www.globenewswire.com/news-release/2026/11/17/3404251/0/en/novartis-cosentyx-becomes-first-and-only-fda-approved-anti-il-17-biologic-for-people-with-polymyalgia-rheumatica-pmr.html"},{"claim":"美國新適應症劑量","value":150,"unit":"mg","as_of":"2026-11-17","source":"https://via.ritzau.dk/files/90446/15292906/612691/en"},{"claim":"REPLENISH研究階段","value":3,"unit":"phase","as_of":"2026-11-17","source":"https://via.ritzau.dk/files/90446/15292906/612691/en"},{"claim":"減量流程期間","value":24,"unit":"week","as_of":"2026-11-17","source":"https://via.ritzau.dk/files/90446/15292906/612691/en"},{"claim":"持續緩解評估時點","value":52,"unit":"week","as_of":"2026-11-17","source":"https://via.ritzau.dk/files/90446/15292906/612691/en"},{"claim":"150mg組持續緩解","value":40.5,"unit":"percent","as_of":"2026-11-17","source":"https://via.ritzau.dk/files/90446/15292906/612691/en"},{"claim":"安慰劑組持續緩解","value":20.5,"unit":"percent","as_of":"2026-11-17","source":"https://via.ritzau.dk/files/90446/15292906/612691/en"},{"claim":"絕對差","value":20,"unit":"percentage_point","as_of":"2026-11-17","source":"https://via.ritzau.dk/files/90446/15292906/612691/en"},{"claim":"同研究NNT換算","value":5,"unit":"person","as_of":"2026-11-17","source":"https://via.ritzau.dk/files/90446/15292906/612691/en"},{"claim":"150mg組嚴重不良事件","value":15.9,"unit":"percent","as_of":"2026-11-17","source":"https://via.ritzau.dk/files/90446/15292906/612691/en"},{"claim":"安慰劑嚴重不良事件","value":14.2,"unit":"percent","as_of":"2026-11-17","source":"https://via.ritzau.dk/files/90446/15292906/612691/en"},{"claim":"Kevzara作用標的","value":"IL-6 receptor","unit":"target","as_of":"2026-11-17","source":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761037s013lbl.pdf"},{"claim":"Cosentyx作用標的","value":"IL-17A","unit":"target","as_of":"2026-11-17","source":"https://www.ema.europa.eu/en/documents/product-information/cosentyx-epar-product-information_en.pdf"}],"sections":["01｜減少疼痛，還要走得完減藥過程","02｜換一條發炎訊號，選擇增加了","03｜緩解差二十個百分點，安全性也要過關","04｜台灣要分清楚新用途與可近性","參考資料"],"references":[{"title":"Cosentyx PMR FDA approval announcement","source":"Novartis","date":"","url":"https://via.ritzau.dk/files/90446/15292906/612691/en"},{"title":"REPLENISH full-data announcement","source":"Novartis","date":"2026-06-03","url":"https://www.novartis.com/news/media-releases/novartis-cosentyx-pmr-data-new-england-journal-medicine-showed-sustained-remission-vs-placebo-twice-many-patients"},{"title":"REPLENISH NCT05767034","source":"ClinicalTrials.gov","date":"","url":"https://clinicaltrials.gov/study/NCT05767034"},{"title":"KEVZARA prescribing information","source":"FDA","date":"","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761037s013lbl.pdf"},{"title":"Kevzara PMR approval announcement","source":"Regeneron","date":"2023-02-28","url":"https://investor.regeneron.com/news-releases/news-release-details/kevzarar-sarilumab-approved-fda-first-and-only-biologic"},{"title":"Cosentyx product information","source":"EMA","date":"","url":"https://www.ema.europa.eu/en/documents/product-information/cosentyx-epar-product-information_en.pdf"},{"title":"Cosentyx European Commission PMR approval","source":"Novartis","date":"2026-10-21","url":"https://www.novartis.com/news/media-releases/novartis-receives-european-commission-approval-cosentyx-polymyalgia-rheumatica-pmr"},{"title":"用藥安全","source":"衛生福利部","date":"","url":"https://www.mohw.gov.tw/cp-88-216-1.html"},{"title":"全民健康保險藥物給付項目及支付標準","source":"全國法規資料庫","date":"","url":"https://law.moj.gov.tw/LawClass/LawAll.aspx?pcode=L0060035"},{"title":"可善挺品名及藥品資料（歷史會議文件","source":"健保署","date":"","url":"https://www.nhi.gov.tw/ch/dl-13689-6b9cfb7d29f6449c9056f62c834aef5b-1.pdf"},{"title":"公司公告分發時間","source":"Novartis／GlobeNewswire","date":"","url":"https://www.globenewswire.com/news-release/2026/11/17/3404251/0/en/novartis-cosentyx-becomes-first-and-only-fda-approved-anti-il-17-biologic-for-people-with-polymyalgia-rheumatica-pmr.html"}],"images":[{"alt":"圖1｜疼痛與減藥是相關的不同目標","url":"https://drugnews.com.tw/assets/articles/cosentyx-pmr-steroid-taper/figure-01.png"},{"alt":"圖2｜Cosentyx 結合 IL-17A 的機制","url":"https://drugnews.com.tw/assets/articles/cosentyx-pmr-steroid-taper/figure-02.png"},{"alt":"圖3｜同研究的持續緩解差","url":"https://drugnews.com.tw/assets/articles/cosentyx-pmr-steroid-taper/figure-03.png"},{"alt":"圖4｜減藥過程需要監測與追蹤","url":"https://drugnews.com.tw/assets/articles/cosentyx-pmr-steroid-taper/figure-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/cosentyx-pmr-steroid-taper/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-11-22）。類固醇減不下來，諾華多一條路。https://drugnews.com.tw/articles/2026-11-22-cosentyx-pmr-steroid-taper.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/","faq":[{"q":"「Cosentyx增加PMR減類固醇的選擇」有哪些關鍵變化？","a":"Cosentyx增加PMR減類固醇的選擇；差異化須比較持續緩解、減量流程及安全性，現有資料沒有與Kevzara直接比較。"},{"q":"「REPLENISH比較指定減量流程下的組間差，沒有與Kevzara直接對打」有哪些關鍵變化？","a":"REPLENISH比較指定減量流程下的組間差，沒有與Kevzara直接對打。"},{"q":"「美國新適應症與台灣在地許可、給付是不同問題」有哪些關鍵變化？","a":"美國新適應症與台灣在地許可、給付是不同問題。"}]}